Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2025
Pancreatic Stone Protein levels reflect sepsis severity and bloodstream infections in critically ill children: a retrospective cohort analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bottari Gabriella, Rosati Francesco, Fegatelli Alunni Danilo, Paionni Emanuel, Ferrigno Federica, Romani Lorenza, De Luca Maia, Lancella Laura, Porzio Ottavia, Bernaschi Paola, Vestri Anna Rita, Ciofi Degli Atti Marta, Raponi Massimiliano, Perno Carlo Federico, Cecchetti Corrado
Аннотация
BACKGROUND: Pancreatic Stone Protein (PSP) has been proposed as a sepsis biomarker, but its role in severity stratification in pediatric intensive care and its relation to infectious source have not been explored.
METHODS: We conducted a retrospective analysis of 97 pediatric patients admitted to the PICU with new-onset sepsis (within 24h from diagnosis). Blood samples were collected within 24h to measure PSP levels and compared with microbiological culture results.
RESULTS: Among 97 patients, PSP levels were significantly higher in those with positive blood cultures (n = 24; median 108 ng/mL) compared with negatives (n = 73; 82 ng/mL, p = 0.008). When combining blood molecular testing with cultures, PSP remained higher in positives (n = 31; 111 ng/mL) than negatives (n = 66; 85 ng/mL, p = 0.026). PSP levels also correlated with sepsis severity: Non-septic (n = 55, median 72 ng/mL), sepsis (n = 22, median 238 ng/mL), septic shock (n = 20, 375 ng/mL) (p = 0.001). Receiver operating characteristic (ROC) curve analysis showed that PSP had superior accuracy in predicting sepsis severity (AUC 0.75, 95% CI 0.64-0.87) compared with C-reactive protein (C-RP, AUC 0.54, 95% 0.37-0.64) and procalcitonin (PCT, AUC 0.60, 95% CI 0.35-0.67).
CONCLUSIONS: PSP is a promising biomarker for sepsis detection and severity prediction in critically ill pediatric patients. Further studies are required to validate its integration into diagnostic protocols.
METHODS: We conducted a retrospective analysis of 97 pediatric patients admitted to the PICU with new-onset sepsis (within 24h from diagnosis). Blood samples were collected within 24h to measure PSP levels and compared with microbiological culture results.
RESULTS: Among 97 patients, PSP levels were significantly higher in those with positive blood cultures (n = 24; median 108 ng/mL) compared with negatives (n = 73; 82 ng/mL, p = 0.008). When combining blood molecular testing with cultures, PSP remained higher in positives (n = 31; 111 ng/mL) than negatives (n = 66; 85 ng/mL, p = 0.026). PSP levels also correlated with sepsis severity: Non-septic (n = 55, median 72 ng/mL), sepsis (n = 22, median 238 ng/mL), septic shock (n = 20, 375 ng/mL) (p = 0.001). Receiver operating characteristic (ROC) curve analysis showed that PSP had superior accuracy in predicting sepsis severity (AUC 0.75, 95% CI 0.64-0.87) compared with C-reactive protein (C-RP, AUC 0.54, 95% 0.37-0.64) and procalcitonin (PCT, AUC 0.60, 95% CI 0.35-0.67).
CONCLUSIONS: PSP is a promising biomarker for sepsis detection and severity prediction in critically ill pediatric patients. Further studies are required to validate its integration into diagnostic protocols.